Call for Wider Use of New Eye Drug in Guernsey as Patients Seek Better Quality of Life

An 82-year-old Guernsey resident says patients’ quality of life is being overlooked due to cost concerns around a new treatment for wet age-related macular degeneration (AMD).

Richard O’Riordan was diagnosed with wet AMD in June and now receives regular injections to protect his sight. He believes local health services should offer Vabysmo, a newer medication that could reduce the number of injections patients need.

“It feels like a no-brainer,” he said. “People’s enjoyment in life is being sacrificed because the cheaper option is chosen. With less frequent injections, patients would benefit hugely.”

A Common Vision-Threatening Condition

Wet AMD is one of the leading causes of sight loss in older adults. It damages the central part of a person’s vision, making reading, driving and recognising faces difficult. The condition typically affects people over 50, and risk factors include ageing, smoking, high blood pressure, obesity and family history.

Treatment Options and the Debate

Vabysmo, introduced in the UK in 2023, can allow for longer gaps between injections depending on progress — potentially improving quality of life for those who require ongoing care.

“Fewer injections mean less stress, less travel and a better daily life,” he said. “At my age, that matters.”